Skip to content

Effectiveness of N-acetyl cysteine(NAC) and vitamin C in patients with endometriosis

Effectiveness of N-acetyl cysteine(NAC) and vitamin C in patients with endometriosis

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
IRCT
Registry ID
IRCT20220817055727N2
Enrollment
48
Registered
2023-07-28
Start date
2023-09-23
Completion date
Unknown
Last updated
2023-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Endometriosis. Endometriosis, unspecified

Interventions

Intervention 1: In this study, people are divided into 3 intervention groups
Before and 12 weeks after the treatment, with the patient s consent, the serum levels of IL-6 and TNFa are checked with an ELISA device, ultrasound of the abdomen and pelvis to detect endometriosis le

Sponsors

Islamic Azad University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 35 Years

Inclusion criteria

Inclusion criteria: Age group 18-35 years old • No menopause • Definitive diagnosis of endometriosis in the last 10 years • Experience of moderate to severe pain (pain score 6-7) • Patients who have resisted common endometriosis treatments or did not respond well to previous treatments. • Written patient consent.

Exclusion criteria

Exclusion criteria: history of chronic pelvic pain that was not due to endometriosis. History of autoimmune, cardiovascular and kidney diseases according to the patient. Abnormal liver enzymes. History of osteoporosis according to the patient. History of other metabolic diseases, including diabetes, dyslipidemia, and metabolic syndrome according to his tests • Simultaneous reception of steroid hormones in different pharmaceutical forms and various doses in the last 3 months • Simultaneous reception of GnRH analogs in the last 3 months • Simultaneous reception of systemic glucocorticoids in the last 3 months • Lack of patient satisfaction

Design outcomes

Primary

MeasureTime frame
Intensity of pain. Timepoint: Before and 12 weeks after treatment. Method of measurement: Vas score questionnaire.;Interleukin-6. Timepoint: Before and 12 weeks after treatment. Method of measurement: ELISA reader device.;TNFa. Timepoint: Before and 12 weeks after treatment. Method of measurement: ELISA reader device.;Abdominal and pelvic ultrasound findings. Timepoint: Before and 12 weeks after treatment. Method of measurement: Ultrasound device.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr.Shahla Chaichian

Islamic Azad University

shchaichian@gmail.com+98 21 2660 2642

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026